What 13 Analyst Ratings Have To Say About CRISPR Therapeutics
Portfolio Pulse from Benzinga Insights
CRISPR Therapeutics (NASDAQ:CRSP) has received 13 analyst ratings in the last quarter, with a majority being bullish or somewhat bullish. The average price target is $77.0, indicating an upside from the current price of $48.86. The average price target has increased by 8.9% over the past month.
August 14, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CRISPR Therapeutics has received mostly bullish ratings from analysts, indicating a potential upside for the stock.
The majority of the 13 analysts have given CRISPR Therapeutics a bullish or somewhat bullish rating. This, combined with an average price target that is significantly higher than the current price, indicates a potential upside for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100